



## **Dawson James Securities Announces the Completion of \$1.0 Million Private Placement Financing for Sigma Labs, Inc.**

**Boca Raton, FL, April 12, 2018** -- Dawson James Securities, Inc. in conjunction with Sigma Labs, Inc., (NASDAQ: SGLB) has closed on the sale to two purchasers in a private placement of an aggregate of 1,000 shares of the Company's newly-created non-voting Series B Convertible Preferred Stock, stated value \$1,000 per share, and warrants to purchase an aggregate of up to 750,000 shares of the Company's common stock, par value \$0.001 per share, for an aggregate purchase price of \$1,000,000. The Series B Convertible Preferred is convertible into 1,000,000 shares of Common Stock based on a conversion price of \$1.00 per share. The Warrants are exercisable for five years commencing six months following the closing of the private placement at an exercise price of \$1.47 per share.

The Company intends to use the net proceeds of this offering (i) to make additional hires with metallurgical and software expertise for the purpose of accelerating and completing the development of tools with Signature/Solution libraries and artificial intelligence facets that are designed to enable sophisticated closed loop control of additive manufacturing machines for real time quality assurance or rescue, (ii) to acquire additional software and customer support personnel for production implementations, and (iii) for other working capital and general corporate purposes.

The net proceeds to Sigma Labs from this offering are anticipated to be approximately \$840,000 after deducting placement agent commissions and other estimated offering expenses payable by Sigma Labs.

Dawson James Securities, Inc. acted as the exclusive placement agent for this offering, and was represented by Schiff Hardin, LLP, Washington, DC.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

For more information regarding the private placement, please refer to the Current Report on Form 8-K filed by Sigma Labs on April 6<sup>th</sup>, 2018.

### **About Sigma Labs, Inc.**

Sigma Labs, Inc. is a provider of quality assurance software under the PrintRite3D® brand and a developer of advanced, in-process, non-destructive quality assurance software for commercial firms worldwide seeking productive solutions for advanced manufacturing. For more information please visit us at [www.sigmalabsinc.com](http://www.sigmalabsinc.com).



## **About Dawson James Securities**

Dawson James Securities specializes in capital raising for small and microcap public and private growth companies primarily in the Life Science/Health Care, Technology and Consumer sectors and is a full service investment banking firm with research, institutional and retail sales, and execution trading and corporate services. Headquartered in Boca Raton, FL, Dawson James is privately held with offices in New York, Maryland and New Jersey. [www.dawsonjames.com](http://www.dawsonjames.com)

## **Safe Harbor Statement**

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Member FINRA/SIPC. For more information, please contact:

**Elise Stern, Managing Director, Head of Capital Markets**

[estern@dawsonjames.com](mailto:estern@dawsonjames.com)

**561-208-2926**